Back to Agenda
Session 5, Part I: Panel Discussion - Implementation, Barriers & Opportunities
Session Chair(s)
Mireille Muller, DRSc, PhD, MSc
Regulatory Policy & Intelligence Director, Novartis Pharma AG, Switzerland
Session 5, Part I: Panel Discussion - Implementation, Barriers & Opportunities
Speaker(s)
Session 5, Part I: Panel Discussion - Implementation, Barriers & Opportunities
Mathieu Boudes, PhD
Patient Engagement Director, Montsouris Consilium, France
Panel discussion with Q&A
Francesco Pignatti, MD
Scientific Adviser for Oncology, European Medicines Agency, Netherlands
Contributing Panelist
Laura Lee Johnson, PhD
Director, Division of Biometrics III, Office of Biostatistics, OTS, CDER, FDA, United States
Contributing Panelist
Bennett Levitan, MD
Executive Director, Benefit-Risk Assessment / Epidemiology, Johnson & Johnson, United States
Contributing Panelist
Michelle Tarver, MD, PhD
Deputy Center Director for Transformation, CDRH, FDA, United States
Contributing Panelist
Irina Cleemput, PhD
Scientific Programme Director, Belgian Health Care Knowledge Centre (KCE), Belgium
Contributing Panelist
Valentina Strammiello, MA
Director of Programmes, European Patients' Forum, Belgium
Contributing Panelist
Menia Koukougianni, MBA
Patient Representative, NGO KARKINAKI AWARENESS FOR CHILDHOOD AND ADOLESCENT CANCER, Greece
Have an account?